<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37344376</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1539-6924</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Risk analysis : an official publication of the Society for Risk Analysis</Title><ISOAbbreviation>Risk Anal</ISOAbbreviation></Journal><ArticleTitle>Worst-case scenarios: Modeling uncontrolled type 2 polio transmission.</ArticleTitle><Pagination><StartPage>379</StartPage><EndPage>389</EndPage><MedlinePgn>379-389</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/risa.14159</ELocationID><Abstract><AbstractText>In May 2016, the Global Polio Eradication Initiative (GPEI) coordinated the cessation of all use of type 2 oral poliovirus vaccine (OPV2), except for emergency outbreak response. Since then, paralytic polio cases caused by type 2 vaccine-derived polioviruses now exceed 3,000 cases reported by 39 countries. In 2022 (as of April 25, 2023), 20 countries reported detection of cases and nine other countries reported environmental surveillance detection, but no reported cases. Recent development of a genetically modified novel type 2 OPV (nOPV2) may help curb the generation of neurovirulent vaccine-derived strains; its use since 2021 under Emergency Use Listing is limited to outbreak response activities. Prior modeling studies showed that the expected trajectory for global type 2 viruses does not appear headed toward eradication, even with the best possible properties of nOPV2 assuming current outbreak response performance. Continued persistence of type 2 poliovirus transmission exposes the world to the risks of potentially high-consequence events such as the importation of virus into high-transmission areas of India or Bangladesh. Building on prior polio endgame modeling and assuming current national and GPEI outbreak response performance, we show no probability of successfully eradicating type 2 polioviruses in the near term regardless of vaccine choice. We also demonstrate the possible worst-case scenarios could result in rapid expansion of paralytic cases and preclude the goal of permanently ending all cases of poliomyelitis in the foreseeable future. Avoiding such catastrophic scenarios will depend on the development of strategies that raise population immunity to type 2 polioviruses.</AbstractText><CopyrightInformation>© 2023 Society for Risk Analysis.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kalkowska</LastName><ForeName>Dominika A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Kid Risk, Inc., Orlando, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiesen</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wassilak</LastName><ForeName>Steven G F</ForeName><Initials>SGF</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Cara C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pallansch</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-1015-4818</Identifier><AffiliationInfo><Affiliation>National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badizadegan</LastName><ForeName>Kamran</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-4900-9455</Identifier><AffiliationInfo><Affiliation>Kid Risk, Inc., Orlando, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Kimberly M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0002-0849-9147</Identifier><AffiliationInfo><Affiliation>Kid Risk, Inc., Orlando, Florida, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NU2RGH001915</GrantID><Acronym>ImCDC</Acronym><Agency>Intramural CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NU2RGH001915</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NU2RGH001915-02-00</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NU2RGH001915-02-00</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Risk Anal</MedlineTA><NlmUniqueID>8109978</NlmUniqueID><ISSNLinking>0272-4332</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001459" MajorTopicYN="N" Type="Geographic">Bangladesh</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">dynamic modeling</Keyword><Keyword MajorTopicYN="N">eradication</Keyword><Keyword MajorTopicYN="N">interdependent risks</Keyword><Keyword MajorTopicYN="N">oral poliovirus vaccine</Keyword><Keyword MajorTopicYN="N">polio</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>22</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>21</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37344376</ArticleId><ArticleId IdType="mid">NIHMS1911577</ArticleId><ArticleId IdType="pmc">PMC10733542</ArticleId><ArticleId IdType="doi">10.1111/risa.14159</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barrett S (2003). Global disease eradication. J Europ Econ Assoc, 1(2/3), 591–600.</Citation></Reference><Reference><Citation>Barrett S (2009). Polio eradication: Strengthening the weakest links. Health Aff, 28(4), 1079–1090.</Citation><ArticleIdList><ArticleId IdType="pubmed">19597207</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett S, &amp; Hoel M (2007). Optimal disease eradication. Environment and Development Economics, 12(5), 627–652.</Citation></Reference><Reference><Citation>Duintjer Tebbens RJ, Hampton LM, &amp; Thompson KM (2016a). Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: Risks of inadvertent trivalent oral poliovirus vaccine use. BMC Infectious Diseases, 16, 231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888482</ArticleId><ArticleId IdType="pubmed">27246198</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Hampton LM, &amp; Thompson KM (2016b). Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: Risks of potential non-synchronous cessation. BMC Infect Dis, 16, 237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888482</ArticleId><ArticleId IdType="pubmed">27246198</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Hampton LM, &amp; Thompson KM (2018). Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use. BMC Infect Dis, 18(1), 165. 10.1186/s12879-018-3074-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-018-3074-0</ArticleId><ArticleId IdType="pmc">PMC5892013</ArticleId><ArticleId IdType="pubmed">29631539</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Hampton LM, Wassilak SGF, Pallansch MA, Cochi SL, &amp; Thompson KM (2016). Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation. J Vaccines Vaccinat, 7(5), 340. 10.4172/2157-7560.1000340</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2157-7560.1000340</ArticleId><ArticleId IdType="pmc">PMC5497833</ArticleId><ArticleId IdType="pubmed">28690915</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Kalkowska DA, &amp; Thompson KM (2018). Poliovirus containment risks and their management. Future Virol, 13(9), 617–628. 10.2217/fvl-2018-0079</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fvl-2018-0079</ArticleId><ArticleId IdType="pmc">PMC7885305</ArticleId><ArticleId IdType="pubmed">33598044</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Jafari H, Cochi SL, Aylward RB, &amp; Thompson KM (2006). Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal, 26(6), 1471–1505.</Citation><ArticleIdList><ArticleId IdType="pubmed">17184393</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Wassalik SGF, Cochi SL, &amp; Thompson KM (2015). An economic analysis of poliovirus risk management policy options for 2013–2052. BMC Infect Dis, 15(389), doi:10.1186/s12879-12015-11112-12878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-12015-11112-12878</ArticleId><ArticleId IdType="pmc">PMC4582932</ArticleId><ArticleId IdType="pubmed">26404632</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, Cochi SL, &amp; Thompson KM (2016). Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infecti Dis, 16, 137. 10.1186/s12879-016-1465-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-016-1465-7</ArticleId><ArticleId IdType="pmc">PMC4806487</ArticleId><ArticleId IdType="pubmed">27009272</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, &amp; Thompson KM (2018). Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. Expert Rev Vaccines, 17(8), 739–751. 10.1080/14760584.2018.1506333</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2018.1506333</ArticleId><ArticleId IdType="pmc">PMC6168953</ArticleId><ArticleId IdType="pubmed">30056767</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative. (2013). Polio eradication and endgame Strategic Plan (2013–2018). World Health Organization. Retrieved Jun 4 2019 from http://polioeradication.org/wp-content/uploads/2016/07/PEESP_EN_A4.pdf</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. (2016). Standard operating procedures: Responding to a poliovirus event or outbreak: Part 1: General SOPs. World Health Organization. Retrieved April 20 2016 from https://s3.amazonaws.com/gpei-tk/reference_links/en/GPEI_SOPs.pdf</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. (2019). Polio eradication and endgame strategic plan (2019–2023). World Health Organization. Retrieved Jun 4 2019 from https://polioeradication.org/wp-content/uploads/2019/06/english-polio-endgame-strategy.pdf</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. (2020). Strategy for the response to type 2 circulating vaccine-derived poliovirus 2020–2021: Addendum to the Polio eradication and endgame strategic plan (2019–2023). World Health Organization. Retrieved Mar 10 2020 from http://polioeradication.org/wp-content/uploads/2020/04/Strategy-for-the-response-to-type-2-circulating-Vaccine-Derived-Poliovirus-20200406.pdf</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. (2021). Polio eradication strategy 2022–2026: Delivering on a promise. World Health Organization. Retrieved Jun 11 2021 from https://polioeradication.org/wp-content/uploads/2021/06/polio-eradication-strategy-2022-2026-pre-publication-version-20210609.pdf</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. (2022). nOPV2: Clinical development summary updated June 2022. World Health Organization. Retrieved 11 Aug 2022 from https://polioeradication.org/wp-content/uploads/2022/06/nOPV2-Clinical-Development-Summary_June-2022-Update_Final-EN.pdf</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. (2023a). Global circulating vaccine-derived poliovirus (cVDPV) as of 25 April 2023. World Health Organization. Retrieved 2 May 2023 from https://polioeradication.org/wp-content/uploads/2023/04/weekly-polio-analyses-cVDPV-20230425.pdf</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. (2023b). GPEI Statement on cVDPV2 detections in Burundi and Democratic Republic of the Congo. World Health Organization. Retrieved 25 April 2023 from https://polioeradication.org/news-post/gpei-statement-on-cvdpv2-detections-in-burundi-and-democratic-republic-of-the-congo/</Citation></Reference><Reference><Citation>Hampton LM, Farrell M, Ramirez-Gonzalez A, Menning L, Shendale S, Lewis I, Rubin J, Garon J, Harris J, Hyde T, Wassilak SGF, Patel M, Nandy R, Chang-Blanc D, &amp; Immunization Systems Management Group of the Global Polio Eradication Initiative. (2016). Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - Worldwide, 2016. Morb Mortal Wkly Rep, 65(35), 934–938. 10.15585/mmwr.mm6535a3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6535a3</ArticleId><ArticleId IdType="pubmed">27606675</ArticleId></ArticleIdList></Reference><Reference><Citation>Independent Monitoring Board of the Global Polio Eradication Initiative. (2022). Highs and lows in the quest for zero, 21st Report, April 2022. Retrieved Aug 24 from https://polioeradication.org/wp-content/uploads/2022/05/21st-IMB-report-20220430.pdf</Citation></Reference><Reference><Citation>Kalkowska DA, Badizadegan K, &amp; Thompson KM (2023). Outbreak management strategies for cocirculation of multiple poliovirus types. Vaccine 10.1016/j.vaccine.2023.04.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.04.037</ArticleId><ArticleId IdType="pubmed">37121801</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, Grotto I, Shulman LM, Anis E, Wassilak SGF, Pallansch MA, &amp; Thompson KM (2015). Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis, 211(11), 1800–1812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7887763</ArticleId><ArticleId IdType="pubmed">25505296</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, &amp; Thompson KM (2014a). Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. J Infect Dis, 210(Suppl 1), S412–S423.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316863</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, &amp; Thompson KM (2014b). Modeling strategies to increase population immunity and prevent poliovirus transmission in two high-risk areas in northern India. J Infect Dis, 210(Suppl 1), S398–S411.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316861</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, &amp; Thompson KM (2018). Another look at silent circulation of poliovirus in small populations. Infect Dis Model, 3, 107–117. 10.1016/j.idm.2018.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idm.2018.06.001</ArticleId><ArticleId IdType="pmc">PMC6326228</ArticleId><ArticleId IdType="pubmed">30839913</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Cochi SL, Kovacs SD, Wassilak SGF, &amp; Thompson KM (2021). Updated characterization of post-OPV cessation risks: Lessons from 2019 serotype 2 outbreaks and implications for the probability of OPV restart. Risk Anal, 41(2), 320–328. 10.1111/risa.13555</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13555</ArticleId><ArticleId IdType="pmc">PMC7814395</ArticleId><ArticleId IdType="pubmed">32632925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, &amp; Thompson KM (2019). Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters. Epidemiology and Infection, 147, e295, Article e295. 10.1017/S095026881900181X</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S095026881900181X</ArticleId><ArticleId IdType="pmc">PMC6813650</ArticleId><ArticleId IdType="pubmed">31647050</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Wassilak SGF, Cochi SL, &amp; Thompson KM (2021). Global transmission of live polioviruses: Updated integrated dynamic modeling of the polio endgame. Risk Anal, 41(2), 248–265. 10.1111/risa.13447</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13447</ArticleId><ArticleId IdType="pmc">PMC7787008</ArticleId><ArticleId IdType="pubmed">31960533</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Wassilak SGF, Cochi SL, &amp; Thompson KM (2023). Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. Vaccine, 41 Suppl 1, A136–A141. 10.1016/j.vaccine.2021.04.061</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.04.061</ArticleId><ArticleId IdType="pmc">PMC11027208</ArticleId><ArticleId IdType="pubmed">33994237</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Wilkinson A, Bandyopadhyay AS, Konopka-Anstadt JL, Burns CC, Oberste MS, Wassilak SGF, Badizadegan K, &amp; Thompson KM (2021). Updated characterization of poliovirus outbreak response strategies for 2019–2029: Impacts of the use of novel OPV2 strains. Risk Anal, 41(2), 329–348. 10.1111/risa.13622</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13622</ArticleId><ArticleId IdType="pmc">PMC7887065</ArticleId><ArticleId IdType="pubmed">33174263</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Voorman A, Pallansch MA, Wassilak SGF, Cochi SL, Badizadegan K, &amp; Thompson KM (2023). The impact of disruptions caused by the COVID-19 pandemic on global polio eradication. Vaccine, 41 Suppl 1, A12–A18. 10.1016/j.vaccine.2021.04.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.04.026</ArticleId><ArticleId IdType="pmc">PMC10045205</ArticleId><ArticleId IdType="pubmed">33962838</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Wassilak SGF, Pallansch MA, Burns CC, Wiesen E, Durry E, Badizadegan K, &amp; Thompson KM (2023). Outbreak response strategies with type 2-containing oral poliovirus vaccines. Vaccine, 41 Suppl 1, A142–A152. 10.1016/j.vaccine.2022.10.060</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.10.060</ArticleId><ArticleId IdType="pmc">PMC10284582</ArticleId><ArticleId IdType="pubmed">36402659</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Wassilak SGF, Wiesen E, Burns CC, Pallansch MA, Badizadegan K, &amp; Thompson KM (2023). Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences. Risk Anal, (in press).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10733544</ArticleId><ArticleId IdType="pubmed">37344934</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles R, Lutterloh E, Schnabel Ruppert P, Backenson PB, St George K, Rosenberg ES, Anderson BJ, Fuschino M, Popowich M, Punjabi C, Souto M, McKay K, Rulli S, Insaf T, Hill D, Kumar J, Gelman I, Jorba J, Ng TFF, . . . Routh J (2022). Public Health Response to a Case of Paralytic Poliomyelitis in an Unvaccinated Person and Detection of Poliovirus in Wastewater - New York, June-August 2022. Morb Mortal Wkly Rep, 71(33), 1065–1068. 10.15585/mmwr.mm7133e2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7133e2</ArticleId><ArticleId IdType="pmc">PMC9400530</ArticleId><ArticleId IdType="pubmed">35980868</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin GR, Peak C, Eisenhawer M, Kurji F, Mach O, Konz J, Gast C, Bachtiar NS, Bandyopadhyay AS, Zipursky S, &amp; n OPVWG (2023). Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience. Vaccine, 41 Suppl 1(Suppl 1), A122–A127. 10.1016/j.vaccine.2022.02.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.02.050</ArticleId><ArticleId IdType="pmc">PMC10109087</ArticleId><ArticleId IdType="pubmed">35307230</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin J, Burns CC, Jorba J, Shulman LM, Macadam A, Klapsa D, Majumdar M, Bullows J, Frolov A, Mate R, Bujaki E, Castro CJ, Bullard K, Konz J, Hawes K, Gauld J, Blake IM, Mercer LD, Kurji F, . . . Zipursky S (2022). Genetic characterization of novel oral polio vaccine type 2 viruses during initial use phase under emergency use listing - Worldwide, March-October 2021. Morb Mortal Wkly Rep, 71(24), 786–790. 10.15585/mmwr.mm7124a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7124a2</ArticleId><ArticleId IdType="pubmed">35709073</ArticleId></ArticleIdList></Reference><Reference><Citation>Rachlin A, Patel JC, Burns CC, Jorba J, Tallis G, O’Leary A, Wassilak SGF, &amp; Vertefeuille JF (2022). Progress toward polio eradication - worldwide, January 2020-April 2022. Morb Mortal Wkly Rep, 71(19), 650–655. 10.15585/mmwr.mm7119a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7119a2</ArticleId><ArticleId IdType="pmc">PMC9098249</ArticleId><ArticleId IdType="pubmed">35552352</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryerson AB, Lang D, Alazawi MA, Neyra M, Hill DT, St George K, Fuschino M, Lutterloh E, Backenson B, Rulli S, Ruppert PS, Lawler J, McGraw N, Knecht A, Gelman I, Zucker JR, Omoregie E, Kidd S, Sugerman DE, . . . Rosenberg ES (2022). Wastewater Testing and Detection of Poliovirus Type 2 Genetically Linked to Virus Isolated from a Paralytic Polio Case - New York, March 9-October 11, 2022. Morb Mortal Wkly Rep, 71(44), 1418–1424. 10.15585/mmwr.mm7144e2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7144e2</ArticleId><ArticleId IdType="pmc">PMC9639435</ArticleId><ArticleId IdType="pubmed">36327157</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM (2022a). Effectiveness of a new vaccine for outbreak response and the increasingly complicated polio endgame. Lancet Glob Health, 10(12), e1697–e1698. 10.1016/S2214-109X(22)00452-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(22)00452-1</ArticleId><ArticleId IdType="pubmed">36400075</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM (2022b). Polio eradication: what kind of world do we want? Lancet Infect Dis, 22(2), 161–163. 10.1016/s1473-3099(21)00458-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(21)00458-8</ArticleId><ArticleId IdType="pmc">PMC8504921</ArticleId><ArticleId IdType="pubmed">34648732</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, &amp; Duintjer Tebbens RJ (2017). Lessons from the polio endgame: Overcoming the failure to vaccinate and the role of subpopulations in maintaining transmission. J Infect Dis, 216(suppl_1), S176–s182. 10.1093/infdis/jix108</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix108</ArticleId><ArticleId IdType="pmc">PMC5853387</ArticleId><ArticleId IdType="pubmed">28838194</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ, &amp; Pallansch MA (2006). Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Anal, 26(6), 1541–1556. 10.1111/j.1539-6924.2006.00843.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1539-6924.2006.00843.x</ArticleId><ArticleId IdType="pubmed">17184396</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, &amp; Kalkowska DA (2020). Review of poliovirus modeling performed from 2000–2019 to support global polio eradication. Expert Rev Vaccines, 19(7), 661–686. 10.1080/14760584.2020.1791093</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2020.1791093</ArticleId><ArticleId IdType="pmc">PMC7497282</ArticleId><ArticleId IdType="pubmed">32741232</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, &amp; Kalkowska DA (2021). Reflections on modeling poliovirus transmission and the polio eradication endgame. Risk Anal, 41(2), 229–247. 10.1111/risa.13484</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13484</ArticleId><ArticleId IdType="pmc">PMC7983882</ArticleId><ArticleId IdType="pubmed">32339327</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA, &amp; Badizadegan K (2022). Health economic analysis of vaccine options for the polio eradication endgame: 2022–2036. Expert Rev Vaccines, 1–8. 10.1080/14760584.2022.2128108</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2022.2128108</ArticleId><ArticleId IdType="pmc">PMC10116513</ArticleId><ArticleId IdType="pubmed">36154436</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA, &amp; Badizadegan K (2023). Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation [Original Research]. Front Public Health, 11. 10.3389/fpubh.2023.1098419</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1098419</ArticleId><ArticleId IdType="pmc">PMC10080024</ArticleId><ArticleId IdType="pubmed">37033033</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Wallace GS, Duintjer Tebbens RJ, Smith PH, Barskey AE, Pallansch MA, Gallagher KM, Alexander JP, Armstrong GL, Cochi SL, &amp; Wassilak SGF (2012). Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response. Public Health Rep, 127(1), 23–37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234395</ArticleId><ArticleId IdType="pubmed">22298920</ArticleId></ArticleIdList></Reference><Reference><Citation>United Kingdom Department of Health &amp; Social Care. (2022). Joint Committee on Vaccination and Immunisation statement on vaccination strategy for the ongoing polio incident. Retrieved Aug 24 from https://www.gov.uk/government/publications/vaccination-strategy-for-ongoing-polio-incident-jcvi-statement/joint-committee-on-vaccination-and-immunisation-statement-on-vaccination-strategy-for-the-ongoing-polio-incident</Citation></Reference><Reference><Citation>World Health Assembly. (2008). Poliomyelitis: mechanism for management of potential risks to eradication (resolution 61.1), WHO, Geneva, 19–24 May 2008. World Health Organization. Retrieved Jun 4 from http://apps.who.int/gb/ebwha/pdf_files/WHA61-REC1/A61_Rec1-part2-en.pdf</Citation></Reference><Reference><Citation>World Health Organization. (2010). Global Polio Eradication Initiative - Strategic Plan 2010–2012. Retrieved Sep 6 from http://www.polioeradication.org/Portals/0/Document/StrategicPlan/StratPlan2010_2012_ENG.pdf</Citation></Reference><Reference><Citation>World Health Organization. (2022). GACVS (Global Advisory Committee of Vaccine Safety) Sub-Committee on nOPV2 Safety June 30, 2022 – Virtual Meeting Summary Note for the Record. Retrieved Aug 24 from https://polioeradication.org/wp-content/uploads/2022/08/GACVS-sub-committee-on-novel-opv2-safety.pdf</Citation></Reference><Reference><Citation>World Health Organization. (2023). Report of the second joint meeting (hybrid) of the WHO Global Advisory Committee on Vaccine Safety and the WHO Advisory Committee on Safety of Medicinal Products, 14–16 December 2022. Wkly Epidemiol Rec, 98(09), 83–92. https://apps.who.int/iris/handle/10665/366343</Citation></Reference><Reference><Citation>Zuckerman NS, Bar-Or I, Sofer D, Bucris E, Morad H, Shulman LM, Levi N, Weiss L, Aguvaev I, Cohen Z, Kestin K, Vasserman R, Elul M, Fratty IS, Geva M, Wax M, Erster O, Yishai R, Hecht-Sagie L, . . . Weil M (2022). Emergence of genetically linked vaccine-originated poliovirus type 2 in the absence of oral polio vaccine, Jerusalem, April to July 2022. Euro Surveill, 27(37). 10.2807/1560-7917.Es.2022.27.37.2200694</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.Es.2022.27.37.2200694</ArticleId><ArticleId IdType="pmc">PMC9479469</ArticleId><ArticleId IdType="pubmed">36111556</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>